Intramuscular hydroxocobalamin injections represent the standard first-line treatment in the NHS: For deficiency without neurological involvement : Initially 1 mg three times weekly for two weeks, followed by maintenance injections every two to three months lifelong (if the underlying cause cannot be corrected)
Read safety information Supporting research A selection of peer-reviewed work on GHK-Cu/Epitalon
Starting BPC-157 earlier in the injury process typically produces better results than waiting until problems become chronic
A method of preventing gait abnormalities in a patient with Parkinson's disease or of improving or restoring to normal the gait of a patient with Parkinson's disease, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to prevent, improve or restore to normal said gait, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 where Ri is one of an N-acyl group, a substituted or unsubstituted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
Temporary sensations like warmth, lightheadedness, or a metallic taste in the mouth can also occur during or after the infusion